Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.36 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.34 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 5/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1655543 | 0.95 | CCNT1 (0.38) | TLR9TLR7SIGMAR1CCNT1CCNA2 | |
| SCHEMBL1654741 | 0.82 | CHRM1 (0.40) | CHRM1AVPR2AVPR1A | |
| SCHEMBL1654652 | 0.77 | DRD2 (0.52) | SIGMAR1 | |
| SCHEMBL10012965 | 0.76 | DRD2 (0.43) | SIGMAR1 | |
| SCHEMBL10011586 | 0.74 | DRD2 (0.41) | HTR7HTR1A | |
| SCHEMBL1654004 | 0.71 | AXL (0.35) | — | |
| SCHEMBL10012640 | 0.71 | DRD2 (0.51) | SIGMAR1 | |
| SCHEMBL1654408 | 0.71 | PLA2G1B (0.48) | — | |
| SCHEMBL1654008 | 0.70 | KDM4E (0.44) | TLR9TLR7HTR1A | |
| SCHEMBL27934814 | 0.70 | DRD2 (0.50) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2675803-A1 | MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS | Elanco Animal Health Ireland Limited (IE) | 2013-12-25 | — | — | EP | disclosed |
| EP-2488521-B1 | MACROCYCLIC INTEGRASE INHIBITORS | ELANCO ANIMAL HEALTH IRELAND (IE) | 2013-12-18 | — | — | EP | disclosed |
| US-20130296330-A1 | MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS | ELANCO ANIMAL HEALTH IRELAND LIMITED (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130296330-A1 | MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS | ELANCO ANIMAL HEALTH IRELAND LIMITED (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130296330-A1 | MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS | ELANCO ANIMAL HEALTH IRELAND LIMITED (US) | 2013-11-07 | — | — | US | disclosed |
| US-8497270-B2 | Macrocyclic integrase inhibitors | ELANCO ANIMAL HEALTH IRELAND LIMITED (US) | 2013-07-30 | — | — | US | disclosed |
| WO-2012112345-A1 | MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS | ELANCO ANIMAL HEALTH IRELAND LIMITED (US) | 2012-08-23 | — | — | WO | disclosed |
| EP-2488521-A1 | MACROCYCLIC INTEGRASE INHIBITORS | Elanco Animal Health Ireland Limited (IE) | 2012-08-22 | — | — | EP | disclosed |
| EP-2487176-A1 | Macrocyclic integrase inhibitors for use in the treatment of feline immunodeficiency virus | Elanco Animal Health Ireland Limited (IE) | 2012-08-15 | — | — | EP | disclosed |
| EP-2487176-A1 | Macrocyclic integrase inhibitors for use in the treatment of feline immunodeficiency virus | Elanco Animal Health Ireland Limited (IE) | 2012-08-15 | — | — | EP | disclosed |
| US-20120172367-A1 | MACROCYCLIC INTEGRASE INHIBITORS | ELANCO ANIMAL HEALTH IRELAND LIMITED (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172367-A1 | MACROCYCLIC INTEGRASE INHIBITORS | ELANCO ANIMAL HEALTH IRELAND LIMITED (US) | 2012-07-05 | — | — | US | disclosed |
| WO-2011045330-A1 | MACROCYCLIC INTEGRASE INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011045330-A1 | MACROCYCLIC INTEGRASE INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296330-A1 | MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS | FIP1L1, PIM1, TYMP | TLR9 2186/4885TLR7 2805/4885SIGMAR1 4728/4885 |
| US-20120172367-A1 | MACROCYCLIC INTEGRASE INHIBITORS | CCNI, CCNY, CDK7 | TLR9 3567/4885TLR7 2217/4885SIGMAR1 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.